Life Sciences Investment Trends Taking Shape in 2021
See why two Commercial Banking experts are bullish on venture capital investment in the life sciences sector this year.
The COVID-19 pandemic led to a record high in venture capital investment in life sciences last year. Will that momentum continue in 2021?
Commercial Banking’s Co-Head of Healthcare and Life Sciences, Peter Meath, thinks so.
“There has been no better time, at least in my career, to start a business in life sciences in terms of the pace of innovation, the attention to the space, and the amount of capital that’s focused on the space right now,” Meath said in an interview with MedCity News. “It’s certainly pretty impressive to behold.”
Meath also discussed:
- How investments in COVID-19 testing and track-and-trace technology helped lead the way
- Why an increasing number of investors are backing early-stage life science companies
- The intersection of technology and biopharma—and the growing digital therapeutics sector
- The role SPACs may play this year in the healthcare and life sciences industries
Venture Capital Outlook
Meath’s colleague dug deeper into healthcare and life science funding trends during the MedCity INVEST Conference in April 2021.
In just 12 minutes, Skip Kelly, Relationship Executive for the Venture Capital Coverage group within J.P. Morgan Commercial Banking, outlines how the COVID-19 pandemic forever altered the industry by spurring growth and innovation, ultimately leading to new capital opportunities.
Learn more about industry trends, the changes in debt markets and the outlook for venture capital in 2021.